Cancer Biologics Market Size, Share & Trends Analysis Report By Product (Monoclonal Antibodies, Vaccines, Cell and Gene Therapy, Others), By Applications (Hospitals, Clinics, Others), By End Use, By Region, and Segment Forecasts - 2035

Cancer Biologics Market Overview

The cancer biologics market was valued at USD 181901.25 million in 2025, The market is set to reach USD 204638.91 million by 2026-end and grow at a CAGR of 12.5% between 2026-2035 to reach USD 564380.56 million by 2035.

The Cancer Biologics Market is expanding due to the global cancer burden exceeding 19.9 million new cases and 9.9 million deaths annually, with biologics accounting for nearly 55% of all oncology drug approvals in the last 5 years. More than 1,200 biologic molecules are currently in oncology pipelines across 45 countries. Monoclonal antibodies represent approximately 48% of approved biologic therapies, while cell and gene therapies contribute nearly 12% of late-stage trials. Over 60% of oncology clinical trials initiated in 2024 involved biologics-based mechanisms. More than 70% of targeted cancer therapies introduced after 2015 are biologic in origin.

The USA represents approximately 42% of the global Cancer Biologics Market Share, driven by over 1.9 million new cancer diagnoses and 609,000 cancer-related deaths annually. More than 65% of oncology prescriptions in tertiary hospitals include at least 1 biologic therapy. Over 800 active oncology biologics clinical trials are conducted across 50 states. Approximately 75% of CAR-T therapy centers are located in urban academic hospitals. The U.S. accounts for nearly 50% of global monoclonal antibody production capacity, with more than 120 FDA-approved oncology biologics currently available.

• 

  Download Free sample to learn more about this report.

Key Findings

• Key Market Driver:Approximately 68% rise in targeted therapy adoption, 72% increase in immunotherapy prescriptions, 64% expansion in biologics clinical trials, and 58% improvement in survival rates with biologic-based regimens.
• Major Market Restraint:Nearly 47% treatment cost burden, 39% reimbursement limitations, 33% manufacturing complexity constraints, and 29% adverse event management challenges impacting therapy access.
• Emerging Trends:Over 61% pipeline focus on immuno-oncology, 44% growth in bispecific antibodies, 36% expansion in CAR-T trials, and 41% adoption of precision biomarker testing.
• Regional Leadership:North America holds 42% share, Europe 28%, Asia-Pacific 22%, and Middle East & Africa 8%, with 70% of late-stage trials concentrated in North America and Europe.
• Competitive Landscape:Top 5 companies account for nearly 57% market share, top 10 represent 78%, with 66% of biologics patents held by multinational firms and 49% of pipeline assets in Phase II or III.
• Market Segmentation:Monoclonal antibodies represent 48%, vaccines 9%, cell and gene therapy 15%, and others 28%; lung cancer accounts for 21%, breast cancer 18%, blood cancers 17%, prostate 12%, others 32%.
• Recent Development:Over 34% increase in bispecific antibody approvals, 29% rise in CAR-T manufacturing sites, 31% improvement in checkpoint inhibitor combinations, and 26% expansion in ADC indications.

Cancer Biologics Market Latest Trends

The Cancer Biologics Market Trends indicate strong momentum in immunotherapy, with checkpoint inhibitors accounting for nearly 40% of biologics prescriptions in oncology centers. More than 3 million patients globally received immunotherapy-based regimens in 2024. Bispecific antibodies increased clinical representation by 44% between 2022 and 2025, with over 120 molecules in development. CAR-T therapies are approved for more than 7 hematologic indications, with over 30,000 patients treated worldwide.

Antibody-drug conjugates (ADCs) now represent 12% of biologics pipeline assets, with payload potency improvements exceeding 25% in new-generation linkers. Approximately 52% of oncology trials incorporate biomarker stratification, improving response rates by nearly 18% compared to non-stratified approaches. Over 65% of leading oncology hospitals have implemented next-generation sequencing panels covering more than 300 cancer-related genes. The Cancer Biologics Market Outlook highlights that more than 80% of Phase III oncology trials initiated in 2024 involve biologic-based compounds.

Cancer Biologics Market Dynamics

DRIVER

Increasing global cancer incidence and shift toward targeted immunotherapy.

Global cancer incidence reached 19.9 million new cases annually, with lung cancer accounting for 2.2 million cases and breast cancer for 2.3 million cases. Approximately 70% of oncology treatment guidelines now recommend biologics in first- or second-line therapy. Immunotherapy adoption increased by 72% across tertiary hospitals over the past 5 years. Over 60% of metastatic cancer regimens include at least one monoclonal antibody. Survival rates improved by 20% in HER2-positive breast cancer due to biologic therapy integration. The Cancer Biologics Market Growth is strongly linked to precision medicine, with biomarker-guided treatment increasing by 41% globally.

RESTRAINT

High treatment costs and limited reimbursement coverage.

Approximately 47% of oncology patients in low-income countries face affordability barriers to biologic therapies. Manufacturing complexity results in 35% higher production cycle times compared to small molecules. Nearly 39% of healthcare systems impose prior authorization for biologics. Adverse immune-related events occur in approximately 15% of immunotherapy recipients, requiring hospitalization in 4% of cases. Biosimilar penetration remains below 30% in certain markets, limiting price competition.

OPPORTUNITY

Expansion of cell and gene therapy platforms.

More than 2,000 cell and gene therapy trials are ongoing globally, with oncology representing nearly 55%. CAR-T therapy manufacturing facilities increased by 29% between 2023 and 2025. Approximately 48% of pipeline assets focus on solid tumor applications, compared to 32% five years earlier. Tumor-infiltrating lymphocyte (TIL) therapies demonstrate response rates above 30% in advanced melanoma. The Cancer Biologics Market Opportunities are supported by 38% increase in venture funding directed toward next-generation biologics platforms.

CHALLENGE

Complex manufacturing and supply chain logistics.

Biologic manufacturing requires 12–18 months development timelines for cell line optimization. Over 33% of batches require revalidation due to sterility or potency deviations. Cold-chain logistics demand storage at 2–8°C for 90% of approved biologics. Approximately 22% of CAR-T treatments face manufacturing delays exceeding 3 weeks. Regulatory review timelines for biologics average 10–12 months, extending commercialization schedules.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

The Cancer Biologics Market Segmentation is categorized by type and application, with monoclonal antibodies leading at 48%, followed by cell and gene therapy at 15%, vaccines at 9%, and others at 28%. By application, lung cancer accounts for 21%, breast cancer 18%, blood-related cancers 17%, prostate cancer 12%, and others 32%. Over 60% of advanced-stage oncology regimens include biologics. More than 500 biologic molecules are under Phase II and III trials targeting 25 different tumor types.

By Type

Monoclonal Antibodies:Monoclonal antibodies represent 48% of the Cancer Biologics Market Size, with over 120 FDA-approved oncology mAbs globally. Checkpoint inhibitors account for nearly 40% of mAb usage. HER2-targeted antibodies improve 5-year survival rates by 20% in breast cancer. Approximately 65% of metastatic colorectal cancer regimens include mAbs. More than 300 monoclonal antibodies are in active clinical development across 30 countries.

Vaccines:Cancer vaccines account for 9% of the market, with over 150 therapeutic cancer vaccines under investigation. Preventive HPV vaccines have reduced cervical cancer incidence by 70% in vaccinated populations. Personalized neoantigen vaccines show immune response rates above 50% in early trials. Approximately 25% of vaccine pipelines target melanoma and prostate cancer.

Cell and Gene Therapy:Cell and gene therapies represent 15% share, with more than 30,000 patients treated using CAR-T therapies worldwide. Over 400 oncology-focused gene therapy trials are ongoing. Manufacturing success rates improved by 18% with automated bioreactors. Response rates in certain B-cell malignancies exceed 60%.

Others:Other biologics, including cytokines and oncolytic viruses, account for 28% of the Cancer Biologics Market Share. Oncolytic virus therapies demonstrate tumor reduction in 26% of treated melanoma patients. Cytokine therapies are used in 12% of renal cell carcinoma cases.

By Application

Lung Cancer:Lung cancer accounts for 21% of biologics usage, with over 2.2 million new cases annually. Approximately 45% of non-small cell lung cancer patients receive checkpoint inhibitors. Targeted biologics improve median progression-free survival by 6–8 months.

Breast Cancer:Breast cancer represents 18% of demand, with 2.3 million new cases annually. HER2-positive subtype accounts for 15–20% of cases, with biologics improving survival by 30% in early-stage treatment.

Prostate Cancer:Prostate cancer contributes 12%, with 1.4 million new cases annually. Approximately 35% of advanced-stage patients receive biologic immunotherapy or vaccine-based treatments.

Blood-related Cancer:Blood cancers account for 17%, including leukemia and lymphoma. CAR-T therapy achieves remission rates above 60% in refractory B-cell lymphoma. Monoclonal antibodies are used in 70% of lymphoma regimens.

Other:Other cancers contribute 32%, including colorectal and melanoma. Approximately 40% of melanoma patients receive biologic immunotherapy.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

• North America holds 42% share.
• Europe accounts for 28%.
• Asia-Pacific represents 22%.
• Middle East & Africa hold 8%.

North America

North America dominates with 42% Cancer Biologics Market Share, supported by over 2 million annual cancer diagnoses. Approximately 75% of oncology hospitals administer immunotherapy. Over 800 clinical trials are active. CAR-T therapy centers exceed 150 facilities. More than 65% of prescriptions for metastatic cancers include biologics.

Europe

Europe accounts for 28% share, with over 3.7 million new cancer cases annually. Approximately 60% of Western European oncology centers use biologic combination regimens. More than 500 clinical trials are ongoing. Biosimilar adoption exceeds 35% in certain countries.

Asia-Pacific

Asia-Pacific holds 22% share, with over 9 million new cancer cases annually. China and Japan represent nearly 58% of regional demand. Immunotherapy usage increased by 49% in tertiary hospitals. More than 300 oncology biologics trials are active.

Middle East & Africa

Middle East & Africa represent 8% share, with over 1.3 million new cancer cases annually. Approximately 40% of advanced oncology centers use biologic therapies. Immunotherapy adoption increased by 28% between 2022 and 2025.

List of Top Cancer Biologics Companies

• AbbVie
• Johnson & Johnson
• Novartis
• Gilead Sciences
• Roche
• Bristol-Myers Squibb
• Amgen
• AstraZeneca
• Merck & Co
• Takeda
• Merck KGaA
• Seagen
• Eli Lilly
• Ono Pharmaceutical
• Pfizer
• GSK
• Exelixis
• Regeneron
• Innovent
• Hengrui Medicine

Top 2 Companies by Market Share:

• Roche – Holds approximately 14% global oncology biologics share, with over 20 approved biologic cancer therapies and presence in more than 100 countries.
• Bristol-Myers Squibb – Accounts for nearly 11% share, with immunotherapy regimens used in over 1 million patients globally.

Investment Analysis and Opportunities

Investment in the Cancer Biologics Market exceeds 38% allocation of total oncology R&D budgets toward biologic platforms. Over 1,200 oncology biologics are in clinical pipelines. Venture funding in cell therapy startups increased by 36% between 2023 and 2025. Manufacturing capacity expansions rose by 29% globally. Approximately 45% of capital expenditure in oncology manufacturing targets biologic production lines. Biosimilar development programs increased by 31%, enhancing competitive entry. Emerging markets represent 22% of untapped patient populations eligible for biologics. Precision oncology collaborations grew by 40%, focusing on biomarker-driven development.

New Product Development

More than 120 new oncology biologics entered Phase I trials in 2024. Bispecific antibody platforms increased by 44% in development pipelines. ADC payload stability improved by 25% in next-generation constructs. Over 35% of new launches involve combination immunotherapy regimens. Cell therapy automation reduced manufacturing time by 18%. Approximately 52% of new products incorporate companion diagnostics. Tumor-agnostic approvals expanded by 30% between 2023 and 2025. More than 60% of pipeline molecules target PD-1, PD-L1, or CTLA-4 pathways.

Five Recent Developments (2023–2025)

1. In 2023, a leading manufacturer expanded CAR-T capacity by 30%, increasing annual patient slots to over 10,000.
2. In 2024, a major firm received approval for a bispecific antibody covering 3 oncology indications.
3. In 2024, an ADC therapy expanded into 2 additional tumor types, increasing eligible patient population by 18%.
4. In 2025, a checkpoint inhibitor gained approval in combination therapy, improving response rates by 22%.
5. In 2025, a personalized cancer vaccine reported immune activation in 55% of Phase II participants.

Report Coverage of Cancer Biologics Market

The Cancer Biologics Market Report provides comprehensive Cancer Biologics Market Analysis covering 4 regions, 20 countries, and more than 25 tumor types. The Cancer Biologics Market Research Report evaluates over 1,200 pipeline assets, 500 Phase II/III trials, and 120 approved biologics. The Cancer Biologics Industry Report analyzes 4 product categories and 5 application segments with quantitative metrics including patient population exceeding 19.9 million annually. The Cancer Biologics Market Forecast includes adoption rates above 70% in advanced oncology centers and biosimilar penetration levels reaching 35% in selected markets. The Cancer Biologics Market Insights assess clinical success rates averaging 45% in late-stage biologics trials and manufacturing timelines of 12–18 months.